AlloJoin™ Therapy for Knee Osteoarthritis
In January 2016 we launched a Phase I clinical trial of an off-the-shelf allogeneic adipose-derived mesenchymal progenitor cell (haMPC) AlloJoinTM therapy for Knee Osteoarthritis (KOA). SEE TRIAL INFO BELOW
AlloJoinTM therapy is built on our promising technology platform and clinical experience using autologous adipose-derived mesenchymal progenitor cells (haMPC) ReJoin® therapy for the treatment of KOA. In addition to the safety and efficacy being demonstrated in clinical trials for the autologous ReJoin® therapy, the safety profile of allogeneic stem cell therapies in humans has been documented, and animal model studies we have conducted have also provided preliminary evidence of efficacy of allogeneic adipose derived and expanded mesenchymal progenitor cells for treatment of KOA.
The development of an allogeneic product seeks to provide additional benefits to patients and physicians in that it generates a bank of third-party donor haMPCs that can be used for off-the-shelf treatment, allowing for ease of manufacture and use, lower costs and a selection of more healthy donors. This could increase the number of patients that can be treated by a single isolation with the same quality manufacturing procedures.
|Name of Study||Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis|
|Phase||Clinical Trial I|
|Status||Patient Treatment Completed
Three-Month Interim Safety Data released December 2016 VIEW HERE
|ClinicalTrials.gov Identifier||NCT02641860 - view study online here|
|Study Design||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
|Principal Investigator||Chunde Bao, MD|
|Hospital(s)||Shanghai Renji Hospital|